We hope you find everything you need to understand how Idorsia intends to achieve its ambitious goals. If you need any further support please don't hesitate to reach out to us.

Full presentation

The full OnDemand investor webcast runs at 21 minutes and is broken down into the following chapters:

  1. The urgent unmet medical need and significant market opportunity in difficult-to-control hypertension.
  2. The fundamental role of endothelin in hypertension.
  3. The clinical evidence that secured TRYVIO’s approval.
  4. The details of TRYVIO's differentiated profile in high-risk patient populations.
  5. The real-world evidence and market preparation activities currently underway.

Visit the page to also find the slides and transcript.

Shareprice

IDIA SIX Swiss Exchange

2025-08-28 17:31:14 CET

2.72 CHF

+0.03 (+0.93 %)

Events

 Event When
Meet the new CEO / management – London Aug 13, 2025
Meet the new CEO / management – Zurich Aug 20, 2025

Citi's Biopharma Back to School Conference – Boston

 Sep 2-3, 2025
Wells Fargo Healthcare Conference – Boston Sep 3-5, 2025
H.C. Wainwright Global Investment Conference – New York Sep 8-10, 2025
9-Month 2025 Financial Results reporting Oct 30, 2025
Citi's Global Healthcare Conference – Miami Dec 2-4, 2025
Evercore Annual Healthcare Conference – Miami Dec 2-4, 2025
Full-Year 2025 Financial Results reporting Feb 26, 2026

*We will be in a silent period for 10 days ahead of the financial reporting.

Financial overview

The company reports on its financial performance on a quarterly basis starting its financial year on January 01. Get the latest highlights, financial results, company funding status, as well as a 5-year archive of our financial reporting.
 

Stock overview

The registered shares of Idorsia Ltd are listed on the SIX Swiss Exchange (symbol: IDIA). Get all the latest information about our stock and see what the covering analysts think about the company's future performance.